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Abstract
Background: Study to investigate the intussusception incidence background in the pediatric population and its
temporal trend in Italy.
Methods: A cross-sectional study was conducted on the pediatric population aged 0 to 15 years, in the period 1
January 2002 to 31 December 2012. Intussusception cases were identified using the national hospital discharge
database. The annual intussusception incidence, the incidence rate ratios (IRRs) and the related 95 % confidence
Intervals (CI) were calculated.
Results: The overall intussusception incidence rate was 21 per 100,000 children aged ≤15 years, and was higher
among boys than girls. The highest intussusception incidence rate occurred in infants <1 year of age (39 per
100,000 infants). Among infants, incidence varied with the geographical area, with higher rates in the central Italy
(50 per 100,000 infants).
The annual incidence rates in infants were stable since 2004 and up to 2012, ranging from 40.1 and 33.0 per
100,000 infants. Similar stable patterns were observed when conducting the analysis on children over 1 year of age.
Conclusions: This study provided the intussusception incidence background in Italy in different pediatric ages,
including infants, over an 11-year period. This information is essential in post-marketing safety surveillance, to
continuously monitor the benefit/risk profile of rotavirus vaccinations.
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Background
Intussusception is the most common cause of acute in-
testinal obstruction in children under 2 years of age [1].
Less than 5 % of cases resolve spontaneously and if
treated early, almost all cases can be reduced by enema
or surgery [2].
The etiology of intussusception is unknown for most
of the cases, although some conditions have been found
associated [3–8].
Rotashield®, the first-generation rotavirus vaccine (RV)
was found to be associated with intussusception in in-
fants, leading to its withdrawal from the market in 1999
[8]. In Italy two different RVs (Rotarix® and Rotateq®)
have been available on the market since 2007, being ad-
ministered as a two-or three-dose schedule starting from
6 weeks of age [9, 10]. Neither of the two licensed RV
were found to be associated with intussusception in clin-
ical trials [11, 12]. However, post-marketing studies en-
rolling much larger population have suggested an
intussusception risk following RV vaccination, which is
in 2 to 5 excess cases per 100,000 vaccinated infants
[13–16].
Although vaccination against rotavirus is not included
in the universal National Immunization Program (2012–
2014), some Italian regions introduced the RV targeting
specific children subgroups and/or with different reim-
bursement schemes [17]. According to official data in
Italy during 2013, approximately 76,000 vaccine doses
were purchased within the Italian national health system
(NHS), resulting in almost 37,000 vaccinated children
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(13,700 doses were purchased in 2010 by the NHS) [18,
19]. This led the Italian Pharmacovigilance Network to
capture the first spontaneous intussusception report in
2012 [18].
According to literature, the EU intussusception inci-
dence background in the pediatric population ranges be-
tween 0.66 and 2.24 per 1000 children admitted to
hospital, and between 0.75 and 1.00 per 1000 children
admitted to the emergency ward [20]. This estimate was
largely based on hospital discharge data collected before
1995. A more recent review estimated the intussuscep-
tion incidence background in infants (aged ≤1 year) ran-
ging between 20 and 66 per 100,000 infants [21]. The
reported incidence in different countries varies largely,
possibly due to different factors (age, patient settings
and pathological conditions, socioeconomic status, and
geographical area) [20, 21]. Only one incidence study
was conducted in Italy in a primary care pediatric setting
(children aged <10 years) and provided an estimate of
5.0 per 100,000 person-years [22]. However, it is well
known that intussusceptions cases are generally treated
in a hospital setting [21].
The use of RV is expected to increase in Italy, thus
any post-marketing surveillance would require intussus-
ception incidence background data from reliable and
stable sources.
Therefore, a cross-sectional study was conducted
based on the national database of hospital discharges in
the period 1 January 2002 to 31 December 2012. The
study was aimed to determine the overall intussuscep-
tion incidence in the pediatric population in Italy, and to
describe its temporal trends over a period of time in spe-
cific age groups. The study included the evaluation of in-
cidence patterns according to intussusception severity,
gender, geographical area, and pathological lead points.
The potential changes of intussusception rates in differ-
ent timeframes was also explored in infants, before and
after 2007 (before and after the marketing authorization
of RV in Italy).
Methods
Population and study settings
The study was conducted on the Italian pediatric popu-
lation aged 0 to 15 years; cases were identified from
hospitalization records. Only children with an intussus-
ception discharge diagnosis in the study period were in-
cluded. Two different sub-cohorts were identified for the
main analyses, i.e. infants aged 0 to < 1 years and chil-
dren aged ≥ 1 year of age.
Data sources
In Italy the NHS is provided universally free. A hospital
database collects all hospital discharge records (includ-
ing day-hospital/day-surgery admission). Only routinely
collected information was used in the study and data were
analyzed through a unique, anonymised, personal identi-
fier. The following data were extracted for the present
analyses from each record: age, gender, region of resi-
dence, admission and discharge dates, diagnosis (primary
and secondary) and procedures [coded according to the
International Classification of Diseases (ICD), 9thRevi-
sion],status at discharge (deceased/non-deceased).
Case definition
Records with the following intussusceptionICD-9 codes,
either as primary or secondary diagnosis, were selected
from the national database hospital discharge records:
560.0 (intussusception) and 543.9 (other and unspecified
appendix diseases). The analysis was restricted to incident
cases identified from 1 January 2002 to 31 December
2012; thus, only the first intussusception-associated hospi-
talizations (considered as index dates) were included.
Identification of risk factors potentially associated with
intussusception
To identify potential risk factors for intussusception, all
hospitalization records in the 6-month period preceding
the index date (the first intussusception diagnosis) for
each identified case were retrieved. Hospitalization re-
cords in 2001 were used to collect the medical history of
intussusception case incidents in 2002. A predefined list
for the leading points pathology was used with the re-
lated ICD-9 codes (see Additional file 1: Annex 1).
Case Severity
As a proxy for the case severity, ICD-9 procedure codes
were used to identify those intussusception hospitaliza-
tions requiring surgical or radiological intervention. Sur-
gical intervention was defined by procedure codes 46.80
to 46.82, and radiological intervention by codes 96.29
and 96.39. All the procedure codes were coupled to an
intussusception code, namely in the same hospital dis-
charge form of the intussusception incident case. Three
categories were defined: i) intussusception (identified by
diagnosis); ii) intussusception requiring surgery (identi-
fied by diagnosis and surgical procedures); iii) intussus-
ception requiring non-surgical intervention (identified
by diagnosis and non-surgical procedures). The in-
hospital mortality was also evaluated (number of chil-
dren who died in-hospital following the first intussus-
ception episode).
Intussusception Recurrence
Consecutive intussusception hospitalizations for the
same child were identified for up to 1 year following the
first episode of intussusception (incident case). The same
ICD-9 codes applied to identify incident cases were used
to retrieve recurrence of intussusception episodes. Three
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categories of recurrence were defined: i) early recur-
rence: cases with hospital readmission ≤7 days from the
first episode; ii) medium term recurrence: cases with
hospital readmission between 8 and 30 days from the
discharge; iii) late recurrence: cases with hospital re-
admission after 30 days from the discharge and ≤1 year.
Statistical analysis
The annual intussusception incidence per 100,000 infants/
children was calculated using as a reference the Italian
population resident figure provided by the National Insti-
tute for Statistics, for the period 2002 to 2012 [23]. Births
were assumed to be evenly distributed throughout the
year, when hospitalization rates by age (in months) were
calculated. Intussusception period specific incidence rates
associated with hospitalization were estimated. Annual in-
cidence rates were calculated after being adjusted by age
and gender, through direct standardization methods, using
the 2012 population as a reference to take into account
the ongoing demographic variation.
The incidence rate ratios (IRRs), and the 95 % Confi-
dence Intervals (CI) were calculated through the Poisson
regression. Statistical analyses were performed using
STATA software (version 11.2; Stata Corp LP, College
Station, TX, USA) and IBM SPSS Statistics for Windows
(Version 22.0; Armonk, NY: IBM Corp.).
Results
Overall, 20,524 children aged 0 to 15 years were identi-
fied as intussusception incident cases during the 2002 to
2012 timeframe, 2344 were infants aged 0 to < 1 year
(Fig. 1).
Intussusception incidence rates by age, gender,
geographical area, severity and risk factors
The description of the characteristics of the overall
pediatric population enrolled is shown in Table 1. The in-
tussusception incidence rate was 21 per 100,000 children
and was higher among boys than girls (23 per 100,000 vs
19 per 100,000, respectively); thus boys had a statistically
significant increased probability to experience intussus-
ception hospitalization (IRR: 1.16; 95 % CI 1.13–1.20).
Rates of intussusceptions also varied substantially by age,
with the highest incidence rate occurring in infants <1 year
of age (39 per 100,000 infants). However, rates were low
for infants <14 weeks (19 per 100,000 infants in the group
aged 6 to 14 weeks), then increased rapidly, peaking at 60
per 100,000 for infants aged 25 to 32 weeks, then decreas-
ing for children ≤6 years of age; a rise in the
hospitalization incidence rates occurred also within age
groups 10 to 12 years (26 per 100,000 children). The prob-
ability of intussusception hospitalization became statisti-
cally significant higher from 15 weeks of age to ≤52 weeks
(the risk was quadrupled for infants aged 25 to 32 weeks,
IRR: 3.94, 95 % CI 3.15–4.93.). The incidence rates mea-
sured in the overall pediatric population varied by geo-
graphical areas, showing a marked increase in rates in the
south and central Italy, with respect to the north of Italy
(IRR south: 2.65; 95 % CI 2.56–2.74; IRR central: 1.61;
95 % CI 1.54–1.68).
In the vast majority of cases (87.7 %) non-surgical,
or -radiological procedures were reported, shown in
Table 1.
Overall, 8 children hospitalized for intussusception
died in-hospital (3 in the first year of life), with an in-
hospital mortality rate of 0.39 per 1000, in the study
population. The incidence rate of in-hospital mortality
Fig. 1 Flowchart of the enrolled cohort of children with incident hospitalization for intussusception
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following intussusception in infants (<1 year of age) was
0.5 per million infants (Additional file 1: Figure S1).
About 4 % of the children hospitalized with an intus-
susception diagnosis had a recurrence within 1 year after
the first episode (Table 1). The 41.6 % of children experi-
encing a recurrence were hospitalized ≤30 days from the
intussusception incident episode (Additional file 1: Fig-
ure S2).
Only 291 (1.4 %) children showed at least one known
intussusception risk factor in the 6-month period prior
to the incident episode (Table 2). The most frequent risk
factors were presented in Table 2 and included
gastroenteritis (44.3 % of the cases) followed by inflamed
appendix, and Henoch-Schonlein purpura (35.1 % and
9.6 %, respectively).
Intussusception incidence rate temporal trends in infants
and children aged at least 1 year
The annual incidence rate in children <1 year of age was
highest in 2002 and decreased steadily to 2004 falling
from 50.2 to 39.2 per 100,000 infants, rates then
remained stable from 2005 to 2012, ranging from 33.0 to
40.1 per 100,000 infants (Fig. 2a). Stable temporal trends
were observed when considering incidence rates by gen-
der, with constantly higher incidence rates in boys in
each year.
Similar temporal trends were observed when the ana-
lysis was conducted among children aged 1–15 years
(Fig. 2b), although the incidence was lowest in this
population (ranging from 17.6 to 22.6 per 100,000 chil-
dren in the considered period).
The annual trends of incidence rates by geographical
areas remained overall stable (Figs. 3a,b). Specifically,
when considering the infants cohort, the highest inci-
dence rates were observed in each year in the central
Italy: decreasing from 66.6 per 100,000 infants in 2002
to 58.5 in 2012. In the central Italy, the highest inci-
dence rate was observed in Tuscany and Umbria; region
specific incident rates in infants were showed in
Additional file 1: Figure S3a.
With regard to the pediatric cohort over 1 year of age,
a constant higher incidence trend in the period 2002 to
2012 was observed in south of Italy which was 3 fold
higher compared to the northern (Fig. 3b). The highest
rates were observed in the Sicily, Puglia and Basilicata
(Additional file 1: Figure S3b).
The attempt in comparing intussusception hospitalization
rates in infants across different time intervals, before and
after 2007 (before and after RV use in Italy), stratified by
age in months did not show any increases in the first year
of age during post-vaccine introduction years, when com-
pared with pre-vaccine introduction rates (Additional file 1:
Table S1). Overall, the IRR of intussusception was 0.92 in
2007–2008 (95 % CI: 0.83–1.03) and 0.89 in 2009–2010
(95 % CI: 0.79–1.00) and 0.87 in 2011–2012 (95 %
CI: 0.77–0.97).
Discussion
This is the first study providing the intussusception inci-
dence background in Italy over an 11-year period in the
whole pediatric population. The determined background
rates in Italy in children <1 year of age (39 per 100,000
infants) is within the ranges reported at the EU level
[21] and in line with those detected in Germany [24],
Finland [25], UK and Ireland [26], and Switzerland [27],
observed over comparable timeframes. The infant
Table 1 Characteristics of intussusception incident cases
included in the overall study cohort (2002–2012)
No. % Incidence
(per 100,000)
IRR (IC 95 %)
Total 20,524 21
Male 11,321 55.2 23 1.16 (1.13–1.20)
Female 9203 44.8 19 Ref
Age
1–5 weeks 89 0.4 15 Ref
6–14 weeks 196 1.0 19 1.22 (0.95–1.57)
15–24 weeks 541 2.6 47 3.04 (2.43–3.80)
25–32 weeks 561 2.7 60 3.94 (3.15–4.93)
33–52 weeks 957 4.7 41 2.69 (2.16–3.34)
1–3 years 2794 13.6 15 1.00 (0.81–1.23)
4–6 years 2699 13.2 15 0.97 (0.79–1.20)
7–9 years 4349 21.2 24 1.56 (1.27–1.93)
10–12 years 4875 23.8 26 1.72 (1.40–2.21)
13–15 years 3463 16.9 18 1.20 (0.97–1.48)
Geographical area
North Italy 4968 24.2 12 Ref
Central Italy 3408 16.6 19 1.61 (1.54–1.68)
South Italy, Sicily
and Sardinia














following the first episode)
Yes 759 3.7
No 19,765 96.3
Trotta et al. Italian Journal of Pediatrics  (2016) 42:89 Page 4 of 8
intussusception incidence measured in Italy is also
closely similar to those detected at the US level [28–32].
Considering the entire pediatric population (aged
≤15 years) the incidence rates observed in Italy (21 per
100,000) is lower than those in other studies conducted
in Norway [33], France [34] or Denmark [35]. However,
it should be noted that all three studies in the men-
tioned countries were conducted in different timeframes,
or with a limited enrolled population, which may explain
the different intussusception incidence estimates when
compared with those of Italy.
In the Italian pediatric population, incidence rates
were found stable over time when considering different
age groups. Few studies have reported details of tem-
poral trends for intussusception. A Danish study re-
ported a constant decrease in the incidence rates of
infants ≤1 year from 1980 to 2001 [35]; this was ex-
plained by a possible shift in the management of intus-
susception from in-patient to short stay hospitalization
in out-patient settings [36]. In some other literature the
annual incidence rate of intussusception hospitalization
was stable in the different calendar years [28, 37].
The higher incidence rate in boys was expected ac-
cording to the already available data [20]. There was a
strong variability in the rates for the Italian geographical
Table 2 Risk factors distribution among intussusception
incident cases included in the overall study cohort (2002–2012)
No. %
Total (at least one risk factor) 291
Inflamed appendix 102 35.1
Gastroenteritis 129 44.3
Cystic fibrosis 5 1.7
Hirschsprung disease 2 0.7
Reduplication/intestinal duplication 1 0.3
Lymphoma 3 1.0
Intestinal tumor 6 2.1
Henoch-Schönlein purpura 28 9.6
Meckel diverticulum 2 0.7
Intestinal polyps (benign tumor) 3 1.0
Peutz-Jeghers syndrome 4 1.4
Nephrotic syndrome 6 2.1
Kawasaki disease 2 0.7
Ectopic pancreas in ileum 1 0.3
Hemolytic-uremic syndrome 1 0.3
Fig. 2 a Intussusception annual incidence rate (2002–2012) in infants <1 year of age standardized by age and gender (using the Italian resident
population in 2012). b Intussusception annual incidence rate (2002–2012) in children 1–15 years of age standardized by age and gender (using
the Italian resident population in 2012)
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regions (from 12/100,000 in the north to 32/100,000 in
the south of Italy) that remained stable in the considered
period. Moreover, geographical variability also appeared
to be influenced by the age groups considered, being
highest in the Centre in infants. Geographical and envir-
onmental variation in intussusception incidence is
known [20, 21]; however, it should be pointed out that
organizationally different clinical practices among the
Italian regions may have contributed to varying rates.
The only Italian study which was conducted in a primary
care setting did not reveal such geographical differences,
as the majority of family pediatricians included in the
study were in the north of Italy [22].
The percentages of serious cases (9.9 %) observed in
this study namely, those requiring surgical procedures
are in line with data reported elsewhere in Europe [21].
However, the estimate of intussusception cases in Italy
requiring enema appears to be too low (2.4 %) compared
to those expected at EU level (77 %) [21]. The in-
hospital intussusception mortality is a rare event in Italy
(about 1 case per 2 million infants), and the rate is lower
than that of the US study [38]. However, hospital-based
data may underestimate the true mortality for intussus-
ception since children dying before being hospitalized,
or after being discharged were not taken into account.
In this study the overall intussusception recurrence
rate of 3.7 % was consistent with previously published
data [37, 39–41]. In our setting, 24.2 % of incident cases
showed intussusception recurrences, ≤7 days from the
first episode. The timing of recurrence was evaluated
only in a few trials included in a recent meta-analysis on
intussusception enema reduction, which showed a low
recurrence rate at 48 h (≤5 %) [41].
The risk factors potentially linked to intussusception
cases identified in this study were consistent with avail-
able data, where gastroenteritis and appendicitis were
frequently recognized as pathological leading points [24,
27, 39–42].
The data in this study do not reveal any change in in-
tussusception hospitalization rates among Italian infants
(≤1 year of age) when comparing different time intervals
before and after 2007 (before and after the marketing
authorization of RV in Italy), although the coverage was
very limited, <1 % of the birth cohort.
The main strength of this study is the large cohort of
children enrolled. Italian birth cohorts were in fact in-
cluded over an 11-year timeframe, thus these findings
should be considered as representative of the whole
country. Moreover, in Italy health care is provided free
to the whole population within the NHS. For this reason,
Fig. 3 a Intussusception annual incidence rate (2002–2012) in infants <1 year of age by geographical area. b Intussusception annual incidence
rate (2002–2012) in children 1–15 years of age by geographical area
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all intussusception hospitalizations were included in this
study.
This study has several limitations. Intussusception
hospitalization was determined on the basis of ICD-9
diagnosis code at hospital discharge without any prior
validation of the diagnosis. Therefore, the Brighton Col-
laboration (BC) case definition on intussusception re-
quiring specific clinical examinations as well as sign or
symptoms not retrievable through hospital records, was
not applicable in the context of our study [43]. However,
a study conducted by Ducharme et al. in Canada, re-
ported ICD-9 codes to be sensitive (89.3 %) and highly
specific (>99.9 %) in identifying patients with intussus-
ception from administrative data [44]. In addition, a US
study conducted in 3 hospitals showed that almost 90 %
of the intussusceptions codes collected from the dis-
charge forms had met the highest level of diagnostic cer-
tainty [28]. Therefore, the mentioned details give
support and negate the possibility of the misclassifica-
tion of intussusception cases of this study.
Since the analysis included in this study is of only
hospitalization data, the intussusception cases managed
in an out-patient setting are not included, leading to a
potential underestimation of the true incidence rate.
However, in Italy pediatric patients with intussusception
(especially infants) were directly admitted to hospital
without any prior primary care referral [22].
Conclusions
Although this study is based on routinely collected data,
it still provides a robust and representative intussuscep-
tion incidence background in Italy in the different age
groups and evaluates its variability over an 11-year
period. This knowledge is essential for post-marketing
safety surveillance on rotavirus vaccinations and to pro-
vide information useful for vaccine-safety policies.
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